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ABSTRACT
Objective To quantify the effect of levothyroxine dose on
risk of fractures in older adults.
Design Nested case-control study.
Setting Population based health databases, Ontario,
Canada.
Participants Adults aged 70 or more prescribed
levothyroxine between 1 April 2002 and 31 March 2007
and followed for fractures until 31 March 2008. Cases
were cohort members admitted to hospital for any
fracture, matched with up to five controls from within the
cohort who had not yet had a fracture.
Main outcome measure Primary outcome was fracture
(wrist or forearm, shoulder or upper arm, thoracic spine,
lumbar spine and pelvis, hip or femur, or lower leg or
ankle) in relation to levothyroxine use (current, recent
past, remote). Risk among current users was compared
between those prescribed high, medium, and low
cumulative levothyroxine doses in the year before
fracture.
Results Of 213511 prevalent levothyroxine users
identified, 22236 (10.4%) experienced a fracture over a
mean 3.8 years of follow-up, 18108 (88%) of whom were
women.Comparedwithremotelevothyroxineuse,current
use was associated with a significantly higher risk of
fracture (adjusted odds ratio 1.88, 95% confidence
interval 1.71 to 2.05), despite adjustment for numerous
risk factors. Among current users, high and medium
cumulative doses (>0.093 mg/day and 0.044-0.093 mg/
day) wereassociatedwitha significantlyincreasedriskof
fracture compared with low cumulative doses
(<0.044 mg/day): 3.45 (3.27 to 3.65) and 2.62 (2.50 to
2.76), respectively.
Conclusion Among adults aged 70 or more, current
levothyroxine treatment was associated with a
significantlyincreasedriskoffracture,withastrongdose-
response relation. Ongoing monitoring of levothyroxine
dose is important to avoid overtreatment in this
population.
INTRODUCTION
Hypothyroidism is common in older people, particu-
larly women,
1 and over 20% of older people receive
levothyroxine replacement long term.
2 With normal
ageing, thyroid hormone production, secretion, and
degradation decreases,
3-5 and therefore older people
with hypothyroidism have lower requirements for
levothyroxine replacement than younger people.
35
Most people with hypothyroidism are diagnosed in
early or middle adulthood,
6 thus most will have been
treated for many years by the time they reach older
age. Although regular monitoring of levothyroxine
doses is indicated,
78 evidence suggests that the dose
often remains unchanged as people age,
910 and over
20% of older adults are overtreated,
11-14 leading to
iatrogenic hyperthyroidism.
Chronic hyperthyroidism may increase the risk of
fractures, particularly in older people and postmeno-
pausalwomenwhoalreadyhaveahigherriskofosteo-
porosis and fractures.
1315-17 Studies have found that
higher compared with lower doses of levothyroxine
replacement
18-20 and subclinical hyperthyroidism
21
are associated with a lower bone density and bone
quality, as measured by ultrasonography.
22 An excess
of thyroid hormone can also affect neuromuscular
function and muscle strength
23 and increase the risk of
arrhythmias
2425 and falls,
15 which can raise the risk of
fractures independent of bone density. Previous stu-
diesoftheassociationbetweenlevothyroxineandfrac-
tures have had mixed results,
1526-30 largely because of
small sample sizes and the inclusion of younger, lower
riskpopulations.Thisproblemhasnot beendealtwith
adequately in older women, and older people in gen-
eral, who are at higher risk of fractures,
152631 more
likely to be treated with levothyroxine,
1132 and more
vulnerable to adverse events related to
overtreatment.
1433-36 Similarly, the effect of levothyr-
oxine dose on risk for fracture has not been explored.
Inthispopulationbasedstudywequantifiedtheriskof
any fracture associated with increasing doses of repla-
cement levothyroxine therapy in older men and
women.
METHODS
We carried out a population based, retrospective
cohort study with a nested case-control design using
population health databases for Ontario, Canada,
linked anonymously by encrypted health card
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all publicly funded drugs dispensed to Ontarians aged
65 or older.
37 The national ambulatory care reporting
system database details visits to emergency depart-
ments, and the Canadian Institute for Health Informa-
tion discharge abstract database provides information
on hospital admissions. Independent comparisons
have validated the discharge abstract database against
hospital medical records, determining accuracy of the
databaseforprocedures,diagnosesfor primaryadmis-
sion,andmajorcomplications,
38-41andhavebeenused
extensively for data on fractures.
42-44 The Ontario
health insurance plan database identifies claims for
physicianservices,andtheregisteredpersonsdatabase
provides information on demographics and death.
DiabetesstatuswasobtainedfromtheOntariodiabetes
database
45 and history of thyroid cancer from the
Ontario cancer registry.
46
Study cohort
The cohort consisted of Ontario residents aged
between70and105yearswithatleastoneprescription
for levothyroxine between 1 April 2002 and 31 March
2007. People entered the cohort on the date of their
first prescription. Although the Ontario drug benefit
database records prescription data for patients starting
atage65years,weexcludedthoseunder70toprovide
at least five years of drug history for all participants.
We excluded people if they had received dialysis or
palliative care in the six months before entry to the
cohort because of differing goals of care or bone
physiology. People were also excluded if they had a
history of thyroid cancer or previous hyperthyroidism
beforeentrytothe cohort,whichmightprompthigher
dose targets for levothyroxine beyond mere replace-
ment.
Study outcomes
The primary outcome was any fracture, defined as the
first visit to an emergency department or admission to
hospital for any fracture of the wrist or forearm,
shoulder or upper arm, thoracic spine, lumbar spine
and pelvis, hip or femur, or lower leg or ankle. We
excluded fractures that occurred in the context of sei-
zure, trauma, bone malignancy (primary or second-
ary), multiple myeloma, or disease. The secondary
outcome was a hip or femur fracture alone, with the
same contextual exclusions. (See web extra for codes
according to international classification of diseases,
ninth and 10th revisions.)
Participants were followed until the first occurrence
ofanoutcomeofinterest,death,initiationofdialysisor
palliative care, diagnosis of thyroid cancer, or the end
of the study period (31 March 2008).
Cases, controls, and matching
We defined a case as any cohort member who had at
least one relevant fracture during follow-up, with the
date of admission to hospital for the first fracture ser-
ving as the index date. For each case we selected up to
Table 1 |Baseline characteristics of cases admitted to hospital for first fracture during follow-
up (cases) and matched with those still at risk for fracture (controls) at index date among
current levothyroxine users
Characteristics Cases (n=20 514) Controls (n=100 660)
Mean (SD) age (years) 82.27 (6.81) 82.17 (6.80)
Age group:
70-79 7484 (36) 36 716 (36.5)
80-84 9764 (48) 48 263 (47.9)
≥90 3251 (16) 15 681 (15.6)
Female 18 108 (88) 89 288 (89)
Resident in long term care facility 3505 (17) 21 306 (21)
Neighbourhood income (fifths):
1 4575 (22) 22 483 (22)
5 3838 (19) 18 002 (18)
Mean (SD) daily levothyroxine dose (mg) at index date 0.09 (0.04) 0.08 (0.04)
Medical comorbidities*
Mean (SD) No of drugs prescribed in past year 11.51 (5.93) 11.93 (6.22)
Charlson comorbidity score:
0 3841 (19) 16 150 (16)
1 3238 (16) 15 276 (15)
≥2 4865 (24) 31 624 (31)
Dementia 6260 (31) 30 409 (30)
Stroke 1560 (8) 8901 (9)
Parkinson’s disease 863 (4) 3777 (4)
Cardiac arrhythmia 6354 (31) 34 221 (34)
Osteoporosis 5544 (27) 22 343 (22)
Chronic renal disease 1946 (9) 12 872 (13)
Diabetes mellitus 4872 (24) 26 036 (26)
Rheumatoid arthritis 1780 (9) 8143 (8)
Inflammatory bowel disease 1331 (6) 6749 (7)
Previous fracture 2044 (10) 10 180 (10)
Prescribed drugs*
Potentially protective drugs:
Bisphosphonates 5701 (28) 23 073 (23)
Statins 6048 (30) 29 380 (29)
Thiazides 3737 (18) 18 733 (19)
Other† 4356 (21) 23 576 (23)
Drugs increasing risk of fracture:
Inhaled or nasal corticosteroids 2759 (13) 14 323 (14)
Oral corticosteroids 1425 (7) 8293 (8)
Proton pump inhibitors 5577 (27) 27 944 (28)
SSRI/SNRIs 5470 (27) 22 675 (23)
Other‡ 1581 (8) 7167 (7)
Drugs increasing risk of fall:
β blockers 5805 (28) 30 438 (30)
Sedatives 6404 (31) 31 082 (31)
Opiates 5570 (27) 26 715 (27)
Antipsychotics 2417 (12) 11 763 (12)
Other§ 2798 (14) 12 379 (12)
Health service use
Visits to family doctor in past year:
0-5 11 540 (56) 58 941 (59)
≥6 8659 (42) 41 719 (41)
Visits to internist in past year:
0-1 16 742 (82) 80 583 (80)
≥2 3757 (18) 20 077 (20)
Admissions to hospital in past year:
0 15 601 (76) 69 294 (69)
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risk for an event on the index date. Controls were
assigned the same index date as their respective case.
Participants could serve as a control more than once
and were later eligible to become a case.
We matched controls to cases on age (within one
year), sex, and duration in cohort (follow-up 30 days
either way).
Levothyroxine use
Cases and controls were defined, according to use of
levothyroxine, as current users, recent past users, or
remote users, based on the timing of their most recent
prescription for levothyroxine before the index date.
The duration of a prescription was calculated as the
number of days supplied for the most recent prescrip-
tion in the Ontario drug benefit database plus an addi-
tional 14 days to allow for non-adherence. We
classified participants as current users if the duration
of their prescription encompassed the index date,
recent past users if the prescription ended
15-180 days before the index date, or remote users if
the prescription ended more than 180 days before the
index date.
The current user subgroup was further categorised
based on the cumulative dose of levothyroxine in the
year before the index date. We determined this dose
bycalculatingthetotalnumberofmilligramsdispensed
from all prescriptions filled in the previous 15 months
intended for drug use in the year before the index date.
If participants had been supplied two different concur-
rent prescriptions for levothyroxine, we used the more
recent dose for the overlapping days. We determined
the distribution of the cumulative daily dose to be a
minimumof0.018mgtoamaximumof158.5mg(med-
ian 24.94 mg). Low dose users were those with a cumu-
lative daily dose in the lowest 25th centile of this
distribution, medium dose users between the 25th and
75thcentiles,andhighdoseusersabovethe75thcentile.
For current users, we examined all the doses of
levothyroxine prescribed in the year before the index
date. If the dose changed, we specified the direction of
the most recent dose change before the index date. An
increaseindosewasconsideredtohaveoccurredifthe
mostrecentdosebeforetheindexdatewashigherthan
the second most recent dose before the index date. A
dosereductionwasnotedifthemostrecentdosebefore
the index date was lower than the second most recent
dose before the index date.
Statistical analysis
We used conditional logistic regression to estimate
associations between levothyroxine use and fracture
outcomes in the matched cases and controls, control-
ling for potential confounders such as fifth of neigh-
bourhood income (from 1 to 5 for the lowest to
highest income fifth), Charlson comorbidity index,
and history of health service use at the index date.
This logistic regression also controlled for other con-
founders, including previous fractures, risk factors for
fracture, and comorbid conditions in the five years
beforetheindexdate,andtheuseofotherprescription
drugs in the year before the index date. The analysis
was done using SAS version 9.2.
For our primary analysis we compared the associa-
tion between any fracture and current use of levothyr-
oxine compared with remote use. We also examined
theassociationbetweenrecentpastusecomparedwith
remote use and fractures to determine whether a resi-
dual effect remained after recent discontinuation of
levothyroxine. We then examined the association
between levothyroxine dose and any fracture in the
subgroup of current users. We compared the risk of
fracture in the high and medium dose groups with
that in the low dose group.
For our first secondary analysis, we examined the
outcome of hip or femur fracture specifically as most
of these fractures are non-traumatic and carry the
greatest morbidity and mortality for older people.
We created a new set of cases and controls, whereby
cases were all cohort members who had experienced a
hip or femur fracture during the observation period
and controls were those who did not experience a hip
or femur fracture. We repeated the primary analyses
for this outcome. Secondly, we compared the risk of
fracture between people who had changed dose in the
pastyearwiththosewhohadnot,consideringanydose
change as well as a dose increase or decrease. Thirdly,
westratifiedthecasesandcontrolsbysexandrepeated
all the primary and secondary analyses for men and
women separately. We also tested for an interaction
between sex and levothyroxine use for each analysis,
to assess whether sex modified the effect of levothyr-
oxine on the risk of fractures.
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RESULTS
The study cohort consisted of 213511 adults using
levothyroxine, with a mean age of 82 and followed
forameanof3.83years.Intotal,22236(10.4%)people
(18108 (88%) women) sustained at least one fracture
and 58063 (27.2%) died during follow-up. Cases
were more likely than controls to have a diagnosis of
osteoporosis and to use bisphosphonates (table 1).
Among the cases, 20514 (92.3%) were current users
of levothyroxine at the index date. Among these,
3071 (15.0%) were low dose users, with a mean daily
doseof0.046mg(SD0.029mg),asdefinedbyacumu-
lative daily dose of less than 15.95 mg over the pre-
vious year (<0.044 mg daily); 10907 (53.2%) were
medium dose users, with a mean daily dose of 0.076
(SD0.026)mg,asdefinedbyacumulativedailydoseof
Characteristics Cases (n=20 514) Controls (n=100 660)
≥1 4898 (24) 31 366 (31)
At least one BMD scan in past 3 years 6295 (31) 27 482 (27)
SSRI=selective serotonin reuptake inhibitors; SNRI=serotonin noradrenaline (norepinephrine) reuptake
inhibitors.
*Unless otherwise listed, medical comorbidities and drugs were scored as yes or no; numbers of yes responses
are listed.
†Include nitrates, calcitonin, oestrogen, and selective oestrogen receptor modulators.
‡Include heparins, anticonvulsants, thiazolidinediones, aromatase inhibitors, and androgen deprivation
treatments.
§Include non-SSRI or SNRI antidepressants and antiparkinsonian drugs.
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Characteristics
Cumulative dose in current users
Low (<0.044 mg/day) Medium (0.044-0.093 mg/day) High (>0.093 mg/day)
Cases (n=3071) Controls(n=27106) Cases (n=10 907) Controls(n=49798) Cases (n=6521) Controls (n=23 756)
Mean (SD) age (years) 83.14 (6.82) 82.56 (6.53) 82.65 (6.86) 82.53 (6.81) 81.22 (6.59) 80.95 (6.94)
Age group:
70-74 971 (32) 9185 (34) 3775 (35) 17 094 (34) 2738 (42) 10 437 (44)
80-84 1515 (49) 13 589 (50) 5257 (48.1) 24 340 (49) 2992 (46) 10 334 (44)
≥90 585 (19) 4332 (16) 1875 (17) 8364 (17) 791 (12) 2985 (13)
Women 2592 (84) 23 157 (85) 9816 (90) 44 992 (90) 5700 (87) 21 139 (89)
Resident in long term care facility 645 (21) 6501 (24) 1819 (17) 10 005 (20) 1041 (16) 4800 (20)
Neighbourhood income (fifths):
1 671 (22) 6116 (23) 2428 (22) 11 062 (22) 1476 (23) 5305 (22)
5 525 (17) 4669 (17) 2137 (20) 9073 (18) 1176 (18) 4260 (18)
Mean (SD) daily levothyroxine dose
(mg) at index date
0.05 (0.03) 0.05 (0.03) 0.08 (0.03) 0.08 (0.03) 0.12 (0.04) 0.12 (0.04)
Medical comorbidities
Mean (SD) No of drugs prescribed in
past year
11.87 (6.17) 12.02 (6.40) 11.31 (5.84) 11.66 (6.05) 11.66 (5.97) 12.41 (6.33)
Charlson comorbidity score:
0 597 (19) 4329 (16) 2031 (19) 8074 (16) 1213 (19) 3747 (16)
1 532 (17) 4417 (16) 1697 (16) 7408 (15) 1009 (15) 3451 (15)
≥2 813 (26) 8608 (32) 2484 (23) 15 050 (30) 1568 (24) 7966 (34)
Dementia 1131 (37) 8918 (33) 3299 (30) 14 866 (30) 1830 (28) 6625 (28)
Stroke 286 (9) 2552 (9) 779 (7) 4155 (8) 495 (8) 2194 (9)
Parkinson’s disease 136 (4) 1101 (4) 469 (4) 1874 (4) 258 (4) 802 (3)
Cardiac arrhythmia 1084 (35) 9690 (36) 3347 (31) 16 715 (34) 1923 (29) 7816 (33)
Osteoporosis 857 (28) 6053 (22) 3090 (28) 11 481 (23) 1597 (24) 4809 (20)
Chronic renal disease 352 (11) 3694 (14) 990 (9) 6224 (12) 604 (9) 2954 (12)
Diabetes mellitus 693 (23) 6857 (25) 2403 (22) 12 059 (24) 1776 (27) 7120 (30)
Rheumatoid arthritis 257 (8) 2134 (8) 901 (8) 3822 (8) 622 (10) 2187 (9)
Inflammatory bowel disease 213 (7) 1818 (7) 702 (6) 3310 (7) 416 (6) 1621 (7)
Previous fracture 447 (15) 3579 (13) 1015 (9) 4511 (9) 582 (9) 2090 (9)
Prescribed drugs
Potentially protective drugs:
Bisphosphonates 842 (27) 6081 (22) 3149 (29) 11 989 (24) 1710 (26) 5003 (21)
Statins 860 (28) 7821 (29) 3222 (30) 14 679 (29) 1966 (30) 6880 (29)
Thiazides 495 (16) 5017 (19) 2048 (19) 9199 (18) 1194 (18) 4517 (19)
Other† 651 (21) 6421 (24) 2281 (21) 11391 (23) 1424 (22) 5764 (24)
Drugs increasing risk of fracture:
Inhaled or nasal corticosteroids 429 (14) 3743 (14) 1416 (13) 6980 (14) 914 (14) 3600 (15)
Oral corticosteroids 201 (7) 1986 (7) 773 (7) 4161 (8) 451 (7) 2146 (9)
Proton pump inhibitors 844 (27) 7455 (28) 2981 (27) 13 862 (28) 1752 (27) 6627 (28)
SSRI or SNRIs 893 (29) 6204 (23) 2866 (26) 11 069 (22) 1711 (26) 5402 (23)
Other‡ 249 (8) 1977 (7) 720 (7) 3150 (6) 612 (9) 2041 (9)
Drugs increasing risk of fall:
β blockers 878 (29) 8230 (30) 3055 (28) 14 735 (30) 1872 (29) 7473 (31)
Sedatives 979 (32) 8118 (30) 3357 (31) 15 393 (31) 2068 (32) 7571 (32)
Opiates 851 (28) 6673 (25) 2821 (26) 12 817 (26) 1898 (29) 7225 (30)
Antipsychotics 432 (14) 3415 (13) 1271 (12) 5617 (11) 714 (11) 2731 (11)
Other§ 399 (13) 3296 (12) 1464 (13) 5802 (12) 935 (14) 3281 (14)
Health service use
Visits to family doctor in past year:
0-5 1658 (54) 15 455 (57) 6221 (57) 29 850 (60) 3661 (56) 13 636 (57)
≥6 1413 (46) 11 651 (43) 4686 (43) 19 948 (40) 2860 (44) 10 120 (43)
Visits to internist in past year:
0-1 2429 (79) 21 526 (79) 9006 (83) 40 292 (81) 5307 (81) 18 765 (79)
≥2 642 (21) 5580 (21) 1901 (17) 9506 (19) 1214 (19) 4991 (21)
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were high dose users, with a mean daily dose of 0.122
(SD 0.041) mg, defined by a cumulative daily dose
greater than 34 mg (>0.093 mg daily). Among the cur-
rent users, those receiving lower doses of levothyrox-
ine were more likely to live in a long term care facility;
to have medical comorbidities affecting fracture risk,
such as dementia
4849 or cardiac arrhythmia
50; and to
have other risk factors for fracture, such as a previous
fracture
335152 or use of selective serotonin reuptake
inhibitors or serotonin noradrenaline (norepineph-
rine) reuptake inhibitors.
5354 Participants receiving
higher doses of levothyroxine were more likely to
havediabetesandwerelesslikelytohaveosteoporosis
(table 2).
Association between levothyroxine treatment and
fractures
Compared with remote use of levothyroxine (discon-
tinued >180 days before index date), current and
recent past use (discontinued within 15 to 180 days of
index date) were both associated with a significantly
increased risk of any fracture (adjusted odds ratio
1.88, 95% confidence interval 1.71 to 2.05 and 1.33,
1.19 to 1.48). Current use compared with remote use
was also significantly associated with an increased risk
of hip fractures (table 3).
Among current users, high cumulative doses of
levothyroxine (>0.093 mg/day) and medium cumula-
tive doses (0.044-0.093 mg/day) were associated with
an increased risk of fractures compared with low
(<0.044 mg/day) doses (3.45, 3.27 to 3.65 and 2.62,
2.50to2.76).Adoserelatedincreaseintheriskoffrac-
tures was also found for hip fractures (table 4).
Compared with remote use of levothyroxine, cur-
rent use was associated with a higher risk of any frac-
ture in bothsexes and witha higherrisk of hip fracture
inwomen.Adoserelatedassociationwasobservedfor
hipfracturesaswellasforanyfractureinbothmenand
women(table 5).Inaddition,interactionsbetweensex
and levothyroxine use and dose were significant
(table 5).Theriskoffractureforcurrentversusremote
use was higher in women than in men, and within the
current user group high dose compared with low dose
was associated with a greater risk in men than in
women (table 5).
Achangeinlevothyroxinedoseinthepreviousyear
was also associated with fewer fractures, although this
was not a significant finding in the adjusted analysis
(0.98, 0.95 to 1.02). However, significant associations
were found when direction of dose change was taken
into account: an increase in dose in the previous year
wasassociatedwithasignificantdecreaseinriskoffrac-
ture (0.90, 0.86 to 0.94) and a decrease in dose was
associatedwithasignificantlyincreasedriskoffracture
(1.09,1.04 to 1.15).Furtheradjustmentof dosechange
by dose categories was not done as only 11-13% of
cases changed dose, and the relative effect of these
changes on risk of fracture was small compared with
the risk estimates from our primary analysis.
DISCUSSION
Our population based study found a significant asso-
ciation between current levothyroxine use and
increased risk of fracture among older people
(>70 years). Furthermore, an increased risk remained
even among those who discontinued levothyroxine
within six months,and a strong dose-responserelation
was observed between current use and risk of fracture.
This increased risk of fractures with treatment was
found in both sexes and persisted despite adjustment
for multiple fracture risk factors. Levothyroxine was
also associated with an increase in hip fractures speci-
fically, which carry the greatest morbidity and mortal-
ity for older adults.
55 Our findings provide evidence
that levothyroxine treatment may increase the risk of
fragility fractures in older people even at conventional
dosages,suggestingthatclosermonitoringandmodifi-
cation of treatment targets may be warranted in this
vulnerable population.
Comparison with other studies
Previous studies examining the association between
levothyroxine replacement and fracture risk have
yielded inconsistent conclusions and have not tackled
the role of levothyroxine dose in this relation. Studies
largely in younger people
30 and postmenopausal
women
1526havenotfoundarelationbetweenanyfrac-
tureorhipfracturesandlevothyroxineuse.Secondary
analyses of other studies have only found associations
between levothyroxine replacement and hip fractures
in men
27 and forearm fractures in older adults within
thefirsttwoyearsoftreatment.
29Recentlyapopulation
Characteristics
Cumulative dose in current users
Low (<0.044 mg/day) Medium (0.044-0.093 mg/day) High (>0.093 mg/day)
Cases (n=3071) Controls(n=27106) Cases (n=10 907) Controls(n=49798) Cases (n=6521) Controls (n=23 756)
Admissions to hospital in past year:
0 2093 (68) 17 225 (64) 8374 (77) 35 240 (71) 5134 (79) 16 829 (71)
≥1 978 (32) 9881 (36) 2533 (23) 14 558 (29) 1387 (21) 6927 (29)
AtleastoneBMDscaninpast3years 839 (27) 6996 (26) 3504 (32) 14 178 (28) 1952 (30) 6308 (27)
SSRI=selective serotonin reuptake inhibitors; SNRI=serotonin noradrenaline (norepinephrine) reuptake inhibitors.
*Unless otherwise listed, medical comorbidities and drugs were scored as yes or no and numbers of yes responses are listed.
†Include nitrates, calcitonin, oestrogen, and selective oestrogen receptor modulators.
‡Include heparins, anticonvulsants, thiazolidinediones, aromatase inhibitors, and androgen deprivation treatments.
§Include non-SSRI or SNRI antidepressants and antiparkinsonian drugs.
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an increased risk of fractures only in those taking
excess levothyroxine replacement based on suppres-
sion of serum thyroid stimulating hormone levels.
28
Our study specifically focused on older adults, who
have a higher baseline risk of fracture
152656 and are
more vulnerable to excessive levothyroxine
replacement.
11-14
Clinical explanation of results
In our study, current use of higher doses of levothyr-
oxine was associated with a higher risk of fractures
compared with lower doses, despite the presence of
fewer risk factors for fracture in high dose users, such
as previous fractures,
335152 stroke,
5758 arrhythmia,
50
dementia,
4849 and the use of certain drugs. Higher
dosesoflevothyroxinearemorelikelytobeassociated
with iatrogenic hyperthyroidism,
3659 which can
decrease bone quality
22 and bone mineral density,
60
leadingtoa higherriskof fracture. Excessthyroid hor-
mone can also increase the risk of arrhythmias
2425 and
muscle weakness
23 in older people, which can contri-
bute to a greater risk of falls.
This association is particularly of concern for
women, given that they were almost 90% of
levothyroxine users in our study. In addition, current
useoflevothyroxinewasassociatedwithalargerriskof
fracture in women than in men. This may be related to
differencesinbodysizeandpharmacokineticsbetween
the sexes.
142861 The notion that the same sized dose of
levothyroxinemayhavedifferenteffectsinwomenand
men is consistent with the finding that the dose-
response curve in current users is steeper in men than
inwomen.Furtherstudiesareneededtoexplorebetter
how the effect of levothyroxine on bone and fracture
risk differs between women and men.
Althoughwe were not able tomeasure thyroidfunc-
tion in our study, we attempted to assess whether
recent dose changes, as a measure of recent thyroid
monitoring, had an effect on fracture risk. We found
a slight increase in fracture risk associated with a
decrease in dose and a small protective effect asso-
ciated with an increase. The mechanism behind these
effects is not clear. A recent decrease in dose may
reflect previous hyperthyroidism, which may predis-
pose to fractures, and an increase in dose may reflect
previous hypothyroidism, which may have been pro-
tective for bone and reduce the risk of fractures. The
small magnitude of this effect limits its clinical signifi-
cance.
Table 3 |Risk for any fracture or hip fracture among all levothyroxine users, stratified by levothyroxine use
Fracture type,
levothyroxine use
No (%) of participants Odds ratio (95% CI)
P value Cases Controls Unadjusted Adjusted*
Any fracture:
Current use† 20 514 (92.3) 96 528 (88.3) 1.88 (1.72 to 2.06) 1.88 (1.71 to 2.05) <0.001
Recent past use‡ 1142 (5.1) 7734 (7.1) 1.31 (1.18 to 1.46) 1.33 (1.19 to 1.48) <0.001
Remote use§ 580 (2.6) 5111 (4.7) 1.00 ——
Hip fracture:
Current use† 7763 (92.1) 36 582 (88.5) 1.58 (1.38 to 1.82) 1.55 (1.35 to 1.78) <0.001
Recent past use‡ 418 (5.0) 2888 (7.0) 1.09 (0.92 to 1.29) 1.12 (0.94 to 1.33) 0.203
Remote use§ 252 (3.0) 1884 (4.6) 1.00 ——
*Adjusted for personal and clinical confounders listed in table 1.
†Number of days supplied for most recent prescription plus 14 days overlapping index date.
‡Prescription ended 15-180 days before index date.
§Prescription ended >180 days before index date (reference group).
Table 4 |Odds ratios for any fracture and hip fracture among current users*, stratified by levothyroxine dose used
Fracture type, cumulative
levothyroxine dose† (mg)
No (%) of participants Odds ratio (95% CI)
P value Cases Controls Unadjusted Adjusted‡
Any fracture:
Low§ (<0.044 mg/day) 3071 (15.0) 27 106 (26.9) 1.00 ——
Medium¶ (0.044-0.093 mg/day) 10 907 (53.2) 49 798 (49.5) 2.61 (2.49 to 2.75) 2.62 (2.50 to 2.76) <0.001
High** (>0.093 mg/day) 6521 (31.8) 23 756 (23.6) 3.38 (3.20 to 3.56) 3.45 (3.27 to 3.65) <0.001
Hip fracture:
Low§ (<0.044 mg/day) 1261 (16.3) 10 635 (28.0) 1.00 ——
Medium¶ (0.044-0.093 mg/day) 4110 (53.0) 18 861 (49.7) 2.55 (2.36 to 2.77) 2.54 (2.34 to 2.75) <0.001
High** (>0.093 mg/day) 2385 (30.8) 8438 (22.2) 3.43 (3.14 to 3.75) 3.39 (3.10 to 3.70) <0.001
*Number of days supplied for most recent prescription plus 14 days overlapping index date.
†Total milligrams of levothyroxine dispensed from all prescriptions in previous 15 months for use in 365 days before index date.
‡Adjusted for personal and clinical confounders listed in table 1.
§Participants whose cumulative levothyroxine dose was in lowest 25th centile of cumulative doses among all cases (mean daily dose 0.046 mg/day).
¶Participants whose cumulative levothyroxine doses was between 25th and 75th centiles of cumulative doses among all cases (mean daily dose
0.076 mg/day).
**Participants whose cumulative levothyroxine doses exceeded 75th centile of cumulative doses among all cases (mean daily dose 0.122 mg/day).
RESEARCH
page 6 of 9 BMJ | ONLINE FIRST | bmj.comClinical application of results
As levothyroxine requirements decrease with age,
iatrogenic hyperthyroidism is more common in older
people.
35Despitethis,studiesshowthatformany peo-
ple levothyroxine dosage is not adjusted as they age
because either monitoring for thyroid dysfunction
may be not be carried out or indicated dose adjust-
ments identified by monitoring may not be
implemented.
9-14 While the optimal levothyroxine
dose for adults is 1.6-1.8 µg/kg/day,
19 older people
often require much lower doses to achieve euthyroid-
ism, and most recommend a reduced dose of 0.5 µg/
kg/dayinseniors(age>65years).
162Whilethedosages
observed in our study were largely appropriate for
youngeradults, the averagedaily dosesin the medium
and high dose categories (0.076 and 0.122 mg/day)
may have exceeded the recommendation for most
people aged over 70. It is also possible that levothyr-
oxine treatment may have deleterious effects on bone
even in people who are biochemically euthyroid.
Recently it has been shown that the risk of vertebral
fractures in older adults is increased with serum thyr-
oidstimulatinghormoneuseinthelowerrangeofnor-
mal limits.
63 To minimise the risk of fracture further
work is necessary to determine whether bone can be
affected by “euthyroid” doses of levothyroxine and
whether treatment targets need to be adjusted in
older people whose true “normal” thyroid stimulating
hormone levels may be higher than thought.
64
Strengths and limitations of the study
Some limitations of our study merit mention. Labora-
tory and radiological data, such as serum thyroid sti-
mulating hormone levels and radiology reports, were
not available from our databases. Also, without access
to clinical information we were unable to verify the
indicationforlevothyroxinetreatmentincohortmem-
bers that affects dosing. This might potentially explain
the larger than expected proportion of people (nearly
8%) who had discontinued levothyroxine, given that it
is generally continued lifelong when prescribed for
hypothyroidism. However, we minimised variation
of indication as much as possible by excluding people
with previous hyperthyroidism or thyroid cancer, and
less than 1% of the study participants had undergone
thyroidectomy. We were unable to measure other fac-
tors that may affect the association between levothyr-
oxine and fracture risk, such as body mass index,
65
family history, smoking, caffeine or alcohol use,
15 or
non-prescriptiondrugusesuchascalciumandvitamin
D. Misclassification and selection bias are also poten-
tial threats to validity in observational studies such as
ours. We minimised the potential for misclassification
by using hospital based fractures as our outcome and
by considering cumulative levothyroxine dosage over
the previous year rather than a single prescription to
estimate drug use.
66 Cases and controls were matched
on age, sex, and duration in the study cohort, and we
used regression techniques to adjust for potential con-
founders.Thenestedcase-controldesigniscommonly
used in pharmacosurveillance research and provides
estimates of effects that are consistent with those
obtained from time to event analysis.
67-70 In addition,
risk factors for fractures and comorbidities were more
common among low dose levothyroxine users, which
would argue against a selection bias explaining the
associationbetween highdoselevothyroxineand frac-
tures. The dose-response relation for levothyroxine
doses commonly prescribed in practice also supports
aclinicallyrelevantassociationbetweenlevothyroxine
treatment and fractures in older people. In using frac-
turesresultinginvisitstotheemergencydepartmentor
hospital admission as our outcome, it is possible that
we failed to capture more minor, asymptomatic frac-
tures that did not seek or warrant hospital based inter-
vention, such as vertebral fractures. The effect of this
onourresultsispossiblyminimal,however,giventhat
ouranalysisusingtheoutcomeofhipfracturesalone,a
Table 5 |Odd ratios for fractures stratified by sex, time of levothyroxine use, and dose
Fracture type, time and dose of
levothyroxine use
Men Women
Interaction between
sex and drug use
No(%)ofcases
Adjusted odds
ratio* (95% CI) P value No(%)ofcases
Adjusted odds
ratio* (95% CI) P value z statistic P value
Any fracture:
Current† v remote 2395 (89.4) 1.42 (1.15 to 1.76) 0.001 18 119 (92.6) 1.98 (1.80 to 2.19) <0.001 −2.80 0.0051
Low‡ (<0.044 mg/day) 479 (20.0) 2592 (14.3)
Medium§ (0.044-0.093 mg/day) 1091 (45.6) 3.18 (2.74 to 3.67) <0.001 9816 (54.2) 2.56 (2.42 to 2.70) <0.001 2.73 0.0063
High** (>0.093 mg/day) 821 (34.3) 4.67 (3.99 to 5.47) <0.001 5700 (31.5) 3.31 (3.13 to 3.51) <0.001 4.00 0.0001
Hip fracture:
Current† v remote 1019 (89.2) 1.14 (0.83 to 1.57) 0.4101 6744 (92.5) 1.65 (1.41 to 1.92) <0.001 −2.04 0.041
Low‡ (<0.044 mg/day) 217 (21.3) 1044 (15.5)
Medium§ (0.044-0.093 mg/day) 440 (43.2) 3.12 (2.49 to 3.89) <0.001 3670 (54.5) 2.46 (2.26 to 2.68) <0.001 1.94 0.052
High** (>0.093 mg/day) 361 (35.5) 5.05 (3.96 to 6.43) <0.001 2024 (30.0) 3.19 (2.90 to 3.51) <0.001 3.46 0.0005
Unadjusted data not shown. Cumulative dose is total milligrams of levothyroxine dispensed from all prescriptions in previous 15 months for use in 365 days before index date.
*Adjusted for personal and clinical confounders listed in table 1.
†Number of days supplied for most recent prescription plus 14 days overlapping index date.
‡Reference group: participants whose cumulative levothyroxine dose was in lowest 25th centile of cumulative doses among all cases (mean daily dose 0.046 mg/day).
§Participants whose cumulative levothyroxine doses was between 25th and 75th centiles of cumulative doses among all cases (mean daily dose 0.076 mg/day).
**Participants whose cumulative levothyroxine doses exceeded 75th centile of cumulative doses among all cases (mean daily dose 0.122 mg/day).
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hospital, yielded the same associations.
Conclusion
Our study shows that levothyroxine treatment is asso-
ciatedwitha higherriskoffracturesinadose-response
manner in older adults, and that dosages commonly
used in clinical practice, especially over 0.093 mg a
day, may be excessive for this population. While
further work is needed to determine whether these
doses are associated with iatrogenic hyperthyroidism
in this population, our study raises concerns that
levothyroxine treatment targets may need to be mod-
ified in elderly people and that dose monitoring
remains essential even into older age.
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